Bevacizumab in ophthalmology: the controversy moves forward.

摘要

At first nothing happened when, based on the encouraging reports from the phase III studies of ranibizumab for neovascular age-related macular degeneration (AMD), Rosenfeld et al. reported a positive response in a case using intravitreal bevacizumab for the same indication in July 2005.l But the peer-reviewed literature lit up from March the following year and it has been going strong ever since at the rate of nearly one new publication per day on the subject of 'bevacizumab AND eye' (http://www.ncbi.nlm. nih.gov/sites/entrez/, accessed 4 April 2010). Clinical indications proposed beyond wet AMD include diabetic retinopathy, retinal vein occlusion, pseudophakic cystoid macular oedema, proliferative diabetic retinopathy, retinopathy of prematurity, radiation retinopathy and macula telangiectasia; and that's just the posterior segment. Reports of bevacizumab for anterior segment disease are now emerging.